Thumb and hand arthritis, especially at the base of the thumb, quietly affects everything from opening jars to paddling and gardening. Regenerative options for the hand are less studied than the knee, but 2025 and 2026 brought new evidence. This article explains what the newest research shows about PRP and cell-based injections for thumb and hand arthritis, and what it realistically means for a patient considering care in Honolulu.
7
studies in a 2025 PRP thumb arthritis meta-analysis
0
stem cell products FDA approved for hand or thumb arthritis
6-24 mo
follow-up where a 2025 thumb cell-injection study reported pain reduction
Most regenerative research has focused on the knee, where the joint is large and easy to study. The hand is a different story: the joints are small, and the evidence base is thinner. That matters, because a treatment shown to help the knee cannot simply be assumed to help the thumb. The newest reviews are honest that high-quality randomized evidence specific to the hand and thumb remains limited.
A 2025 systematic review and meta-analysis of 7 studies and 115 patients found that platelet-rich plasma injection for thumb carpometacarpal (CMC) arthritis reduced pain and improved pinch strength, though gains in grip strength were not statistically significant and the overall evidence quality was limited. A separate 2025 randomized trial for thumb CMC PRP was negative, which is exactly why the field cautions against overstating the results. The honest summary is that PRP shows promise in small, mostly non-randomized studies but is not firmly established for the hand.
“A 2025 systematic review of 7 studies found PRP for thumb CMC arthritis reduced pain and improved pinch strength, while a separate 2025 randomized trial was negative, highlighting how limited the hand evidence still is.”
A 2025 retrospective study evaluated intra-articular injection of autologous conditioned plasma plus stromal vascular fraction and stem cells into the thumb CMC joint in 30 hands of 19 patients. It reported significant pain reduction at 6 and 24 months and suggested the injection may reduce pain and delay the need for surgery in early-stage disease, with minimal risks. Earlier work using bone marrow stem cells with microfracture of the first CMC joint also showed improved pain and range of motion at one year. These are encouraging but small, mostly non-randomized results, and no stem cell product is FDA approved for hand or thumb arthritis.
Broader 2025 and 2026 reviews of intra-articular stem cell injections, drawn largely from knee studies, find that they may modestly improve pain and function for up to about six months, with low to moderate certainty and mostly transient injection-site side effects. The effect specifically for the hand is not well established by high-quality randomized trials. For many patients, the sensible first plan combines hand therapy, activity modification, and ergonomic changes, with a regenerative injection considered only for a specific role and with realistic expectations.
A note from the clinic
Hand and thumb arthritis deserves an honest conversation, because the evidence is thinner here than for larger joints. At Aloha Stem Cell in Honolulu we will walk you through what the research really supports for your specific hand and help you decide whether a regenerative approach fits alongside hand therapy. Call (808) 593-2525 to start.
Our team is happy to listen to your story, answer your questions, and help you decide whether a consultation makes sense. There is no pressure and no obligation.
Keep reading
The FDA now lists Regenecyte, a cord blood stem cell product, among approved cellular therapies. It is a real milestone for blood stem cell transplant patients, and it is not a treatment for joint pain. Here is what the approval is, what it is not, and why it matters when you read stem cell news.
In September 2026 the FDA granted Fast Track status to an experimental cell therapy for ALS, and in August researchers presented new Phase 1/2 data on a stem cell therapy for Parkinson's. Both are real advances and both remain investigational. Here is the honest read.
A stem cell-derived islet therapy restored insulin production in early trials, with 10 of 12 patients insulin-independent at one year. Here is what the 2025-2026 results show, what the FDA has and has not done, and what it means for people with diabetes.
Book a consultation
Pick a time that works for you and our team will confirm your consultation. Questions first? Call us anytime at (808) 593-2525.